Literature DB >> 22706618

Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region).

Chiara Biagi1, Nicola Montanaro, Elena Buccellato, Giuseppe Roberto, Alberto Vaccheri, Domenico Motola.   

Abstract

PURPOSE: Underreporting is a major limitation of spontaneous reporting systems for suspected adverse drug reactions (ADRs). Several interventions to increase the ADR reporting rate have been proposed, but their efficacy remains poorly investigated.
METHODS: This was a questionnaire study aimed at assessing the knowledge, attitudes, and behavior of general practitioners (GPs) regarding ADR reporting and at evaluating whether a monthly e-mail-based newsletter on drug safety could affect the rate and the quality of the ADR reports submitted by these GPs. Three local health authorities (LHAs) of the Emilia-Romagna region were chosen on the basis of their ADR reporting rate during the period preceding the study: Rimini (high), Ferrara (average), and Piacenza (low reporting rate). All GPs (n = 737) associated with these three LHAs were recruited. The pooled number of ADR reports sent by GPs in the remaining seven LHAs of the region was used as controls. The study covered a period of 3 years and was divided into: (1) identification of the reasons leading to underreporting through a questionnaire (Phase I); (2) the intervention, i.e., sending a newsletter for a 10-month period (Phase II); (3) evaluation of the intervention outcomes during the 10 months following the period in which the newsletter had been received (Phase III).
RESULTS: Among GPs involved, 22.8 % returned the questionnaire. Over 94 % of the respondents considered the spontaneous reporting of suspected ADRs to be part of their professional obligations, but only 6.5 % had submitted at least one report in the previous 6 months. Following the completion of Phase II, the overall number of reports coming from the LHAs subjected to the intervention rose by 49.2 % compared to 2009, while the number of reports coming from the control LHAs increased by 8.8 %. Rimini and Piacenza showed a 200 % increase in the number of ADR reports submitted by GPs, while the number of ADR reported submitted by the control group decreased by 25.5 %. In 2011, the number of overall ADRs reports from the LHAs subjected to the intervention decreased by 6.8 %; this decrease reached 50.0 % of the GPs. Control HLAs showed an overall decline of 4.3 %, while the total number of ADRs from GPs increased by 63.3 %. Ferrara was excluded from the analysis due to confounding factors.
CONCLUSIONS: The periodic e-mail update on the safety of drugs represents an effective and inexpensive way to raise the awareness of GPs on the importance of spontaneous ADR reporting. Since the outcome of the intervention seemed to disappear after the intervention was stopped, there appears to be a need to adopt a policy of regular updates and educational strategies for health professionals.

Mesh:

Year:  2012        PMID: 22706618     DOI: 10.1007/s00228-012-1321-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions.

Authors:  J Hasford; M Goettler; K-H Munter; B Müller-Oerlinghausen
Journal:  J Clin Epidemiol       Date:  2002-09       Impact factor: 6.437

2.  Physicians' attitudes and adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; Juan Jesus Gestal-Otero
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial.

Authors:  Adolfo Figueiras; Maria T Herdeiro; Jorge Polónia; Juan Jesus Gestal-Otero
Journal:  JAMA       Date:  2006-09-06       Impact factor: 56.272

4.  Reporting of adverse drug reactions by general practitioners: a questionnaire-based study in the Netherlands.

Authors:  Anneke Passier; Marije ten Napel; Kees van Grootheest; Eugène van Puijenbroek
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system.

Authors:  A Alvarez-Requejo; A Carvajal; B Bégaud; Y Moride; T Vega; L H Arias
Journal:  Eur J Clin Pharmacol       Date:  1998-08       Impact factor: 2.953

6.  Attitudes to adverse drug reaction reporting.

Authors:  W H Inman
Journal:  Br J Clin Pharmacol       Date:  1996-05       Impact factor: 4.335

7.  Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district.

Authors:  M Cosentino; O Leoni; F Banfi; S Lecchini; G Frigo
Journal:  Pharmacol Res       Date:  1997-02       Impact factor: 7.658

8.  Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.

Authors:  Domenico Motola; Antonio Vargiu; Roberto Leone; Anita Conforti; Ugo Moretti; Alberto Vaccheri; Giampaolo Velo; Nicola Montanaro
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 9.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

10.  Influence of an e-mail with a drug information attachment on sales of prescribed drugs: a randomized controlled study.

Authors:  Christina Edward; Anders Himmelmann; Susanna M Wallerstedt
Journal:  BMC Clin Pharmacol       Date:  2007-10-18
View more
  36 in total

1.  Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial.

Authors:  Elena Lopez-Gonzalez; Maria T Herdeiro; María Piñeiro-Lamas; Adolfo Figueiras
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

2.  Reporting of Adverse Drug Reactions in Primary Care Settings in Kuwait: A Comparative Study of Physicians and Pharmacists.

Authors:  Jacinthe Lemay; Fatemah M Alsaleh; Lulwa Al-Buresli; Mohammed Al-Mutairi; Eman A Abahussain; Tania Bayoud
Journal:  Med Princ Pract       Date:  2018-01-29       Impact factor: 1.927

3.  An educational intervention's effect on healthcare professionals' attitudes towards pharmacovigilance.

Authors:  Nisha Jha; Devendra Singh Rathore; P Ravi Shankar; Sudesh Gyawali; Mohamed Alshakka; Shital Bhandary
Journal:  Australas Med J       Date:  2014-12-31

4.  Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA).

Authors:  J L Montastruc; V Rousseau; L Chebane; D Abadie; E Bondon-Guitton; G Durrieu; F Montastruc; H Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2015-07-22       Impact factor: 2.953

5.  Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions.

Authors:  Luca Monaco; Chiara Biagi; Valentino Conti; Mauro Melis; Monia Donati; Mauro Venegoni; Alberto Vaccheri; Domenico Motola
Journal:  Br J Clin Pharmacol       Date:  2017-03-19       Impact factor: 4.335

6.  Pharmacovigilance: empowering healthcare professionals and patients.

Authors:  Stephane Steurbaut; Yolande Hanssens
Journal:  Int J Clin Pharm       Date:  2014-09-05

7.  Ibuprofen-associated hypothermia in children: analysis of the Italian spontaneous reporting database.

Authors:  Monia Donati; Luca Monaco; Mauro Melis; Laura Sottosanti; Chiara Biagi; Alberto Vaccheri; Domenico Motola
Journal:  Eur J Clin Pharmacol       Date:  2016-07-14       Impact factor: 2.953

8.  Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment.

Authors:  A M Kelly; B Smith; Z Luo; B Given; T Wehrwein; I Master; J E Farley
Journal:  Int J Tuberc Lung Dis       Date:  2016-04       Impact factor: 2.373

9.  Comparison of Safety Profiles of New Oral Anticoagulants with Warfarin Using the Japanese Spontaneous Reporting Database.

Authors:  Keiko Hosohata; Saki Oyama; Iku Niinomi; Tomohito Wakabayashi; Ayaka Inada; Kazunori Iwanaga
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

10.  Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).

Authors:  Caterina Palleria; Luigi Iannone; Christian Leporini; Rita Citraro; Antonia Manti; Maurizio Caminiti; Pietro Gigliotti; Rosa Daniela Grembiale; Massimo L'Andolina; Giuseppe Muccari; Maria Diana Naturale; Domenico Olivo; Giuseppa Pagano Mariano; Roberta Pellegrini; Giuseppe Varcasia; Karim Abdalla; Emilio Russo; Francesco Ursini; Giovambattista De Sarro
Journal:  PLoS One       Date:  2018-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.